Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 30, Issue 8, 2008, Pages 643-672

  Tomillero, A ^a   Moral, M A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ASENAPINE; BUTYRIC ACID; CATUMAXOMAB; CEDIRANIB; CLINDAMYCIN; CLOPIDOGREL; DAPOXETINE; DENOSUMAB; ENZASTAURIN; EPOTHILONE B; ETRAVIRINE; EVEROLIMUS; ICLAPRIM; IGURATIMOD; ITRACONAZOLE; LINEZOLID; LOMUSTINE; MAPATUMUMAB; PLACEBO; PRASUGREL; PREGABALIN; PRUCALOPRIDE; PUMOSETRAG; RIMONABANT; TARENFLURBIL; TETRODOTOXIN; TIPIFARNIB; UNINDEXED DRUG; VATALANIB;

ACNE; ACUTE GRANULOCYTIC LEUKEMIA; ALCOHOLISM; ALZHEIMER DISEASE; ARTICLE; ASCITES; BIPOLAR DISORDER; BRAIN CANCER; BRAIN INJURY; BREAST CANCER; CANCER PAIN; CHROMOMYCOSIS; CLINICAL STUDY; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IRRITABLE COLON; LIVER CANCER; LIVER FAILURE; LOADING DRUG DOSE; MICROALBUMINURIA; MULTIPLE CYCLE TREATMENT; NEURALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; OVARY CANCER; PARACENTESIS; PREMATURE EJACULATION; RHEUMATOID ARTHRITIS; SKIN INFECTION; SOLID TUMOR; SPINAL CORD INJURY;

CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 59149101093     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (155)

1. Chan, M., Rusconi, C., Cohen, M. et al. An RNA aptamer inhibiting factor IXa and its complementary oligonucleotide antidote. Eur Heart J 2008, 29(Suppl.): Abst P2063.
2. Behm, M.O., Blanchard, R.L., Murphy, M.G. et al. Assessment of the effect of MK-0974, an oral CGRP receptor antagonist, on spontaneous ischemia in patients with stable cardiovascular disease. Headache 2008, 48(Suppl.): Abst S1.
3. Murphy, S.A., Antman, E.M., Wiviott, S.D. et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008: Adv. Publication.
4. Savoia, C., Touyz, R.M., Schiffrin, E.L. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. J Vasc Res 2008, 45(Suppl. 1): Abst 104.
5. Persson, F., Rossing, P., Schjoedt, K.J. et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008, 73 (12): 1419.
6. Camilleri, M., Specht Gryp, R., Kerstens, R., Vandeplassche, L. Efficacy of 12-week treatment with prucalopride (RESOLOR) in patients with chronic constipation: Combined results of three identical randomized, double-blind, placebo-controlled phase III trials. Gastroenterology 2008, 134(4, Suppl. 1): Abst T1402.
7. Tack, J.F., Ausma, J., Kerstens, R., Vandeplassche, L. Safety and tolerability of prucalopride (RESOLOR) in patients with chronic constipation: Pooled data from three pivotal phase III studies. Gastroenterology 2008, 134(4, Suppl. 1): Abst T1322.
8. Van Outryve, M.J., Beyens, G., Kerstens, R., Vandeplassche, L. Long-term follow-up study of oral prucalopride (RESOLOR) administered to patients with chronic constipation. Gastroenterology 2008, 134(4, Suppl. 1): Abst T1400.
9. Matsueda, K., Hongo, M., Tack, J.F., Saito, Y., Kato, H. Acotiamide (Z-338) is a drug of choice for patients with postprandial distress syndrome of functional dyspepsia. Gastroenterology 2008, 134(4, Suppl. 1): Abst T1028.
10. Matsueda, K., Hongo, M., Sasaki, D. et al. Dose-dependent therapeutic efficacy of acotiamide (Z-338) in patients with functional dyspepsia: 100 mg tid is an optimal dosage. Gastroenterology 2008, 134(4, Suppl. 1): Abst T1027.
11. Paterson, W.G., Ford, D., Ganguli, S.C. et al. A novel, oral 5-HT3 partial agonist, DDP733, improves overall response in patients with irritable bowel syndrome and constipation (IBS-C): A randomized, double blind, placebo-controlled, parallel-group, dose-ranging study. Gastroenterology 2008, 134(4, Suppl. 1): Abst T1397.
12. Herrstedt, J., Arpornwirat, W., Albert, I., Hansen, V.L., Bandekar, R.R., Levin, J., Grunberg, S.M. Safety and efficacy of the novel antiemetic neurokinin1 (NK1) receptor antagonist, casopitant, in women with breast cancer (BC) receiving moderately emetogenic chemotherapy (MEC) - Subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial. Eur J Cancer Suppl 2008, 6(7): Abst 492.
13. Hagen, N.A., du Souich, P., Lapointe, B. et al. Tetrodotoxin for moderate to severe cancer pain: A randomized, double blind, parallel design multicenter study. J Pain Symptom Manage 2008, 35(4): 420.
14. Vranken, J.H., Dijkgraaf, M.G., Kruis, M.R., van der Vegt, M.H., Hollmann, M.W., Heesen, M. Pregabalin in patients with central neuropathic pain: A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2008, 136(1-2): 150.
15. Reid, T.R., Takimoto, C.H., Verschraegen, C.F. et al. Evaluation of safety, tolerability and pharmacokinetics (PK) of patupilone in patients (pts) with advanced solid tumors and varying degrees of hepatic dysfunction: An open-label phase I study. J Clin Oncol 2008, 26(15, Suppl.): Abst 2557.
16. E Silva Azevedo, C.D., Marques, S.G., Resende, M.A. et al. The use of glucan as immunostimulant in the treatment of a severe case of chromoblastomycosis. Mycoses 2008, 51(4): 341.
17. Neumann, A.U., Rozenberg, L., Bain, V.G., McHutchison, J.G., Pulkstenis, E., Subramanian, M. Viral kinetics and pharmacodynamics of albinterferon alfa-2b in interferon treatment-naive patients with genotype 1, chronic hepatitis C. Gastroenterology 2008, 134(4, Suppl. 1): Abst S1939.
18. Yu, M.L., Dai, C.Y., Huang, J.F., Chiu, C.F., Chuang, W.L. Twenty four wks of pegylated interferon alfa-2a (Pegasys) plus ribavirin (Copegus) is as effective as 48 wks regimen in HCV genotype 1 patients with a low viral load achieving an RVR at week 4: A prospective, randomized, controlled study. Hepatol Int 2008, 2(1, Suppl.): Abst PP065.
19. Scott, C., Jogiya, R., Teague, A., Bower, M., Gazzard, B., Nelson, M. Treatment experience with etravirine and optimised background regimen: 24-week data from a single centre cohort. HIV Med 2008, 9(Suppl. 1): Abst P18.
20. Fransen, S., Bridger, G., Whitcomb, J.M. et al. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition. Antimicrob Agents Chemother 2008, 52(7): 2608.
21. Autran, B., Murphy, R.L., Costagliola, D. et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008, 22(11): 1313.
22. Dryden, M., O'Hare, O., Sidarous, E., Hadvary, P., Islam, K. Clinical efficacy of iclaprim in complicated skin and skin structure infection: Preliminary results from the ASSIST-2 clinical trial. Clin Microbiol Infect 2008, 14(Abstracts Issue): Abst P545.
23. Barriere, S.L. Telavancin: A novel lipoglycopeptide for treatment of complicated skin and soft tissue infections. Clin Microbiol Infect 2008, 14(Abstracts Issue): Abst S416.
24. Schumacher, H.R., Jr., Becker, M.A., MacDonald, P.A., Lloyd, E.J., Lademacher, C., Joseph-Ridge, N. Febuxostat (FEB) versus allopurinol (ALLO) in the treatment of gout in subjects more than or equal to 65 years of age. J Am Geriatr Soc 2008, 56(Suppl. 1): Abst C44.
25. Kastelein, J.P.J., Akdim, F., Stroes, S.G.E. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. New Engl J Med 2008, 358(14): 1431.
26. Lü, L.J., Teng, J.L., Bao, C.D. et al. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: A double blind, randomized, placebo-controlled and multicenter trial. Chin Med J 2008, 121(7): 615.
27. Ellis, G.K., Bone, H.G., Chlebowski, R.T. et al. Subgroup analysis of a randomized, phase III study of the effect of denosumab in women with nonmetastatic breast cancer receiving aromatase inhibitor (AI) therapy. J Clin Oncol 2008, 26(15, Suppl.):Abst 546.
28. Parsons, S., Murawa, P.X., Koralewski, P. et al. Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study. J Clin Oncol 2008, 26(15, Suppl.): Abst 3000.
29. Dy, G.K., Croghan, G.A., Qi, Y. et al. Phase I trial of the mTOR inhibitor RAD001 (R) in combination with two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 (P) in patients (pts) with advanced solid tumors. J Clin Oncol 2008, 26(15, Suppl.): Abst 2529.
30. Schelman, W., Morgan-Meadows, S., Bailey, H. et al. A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemother Pharmacol 2008, 62(4): 727.
31. Hotte, S.J., Hirte, H.W., Chen, E.X. et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008, 14(11): 3450.
32. Burris, H.A., III., Infante, J.R., Spigel, D.R. et al. A phase I dose-escalation study of NK012. J Clin Oncol 2008, 26(15, Suppl.): Abst 2538.
33. Bruce, J.Y., Geary, D., De Las Heras, B. et al. Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations. J Clin Oncol 2008, 26(15, Suppl.): Abst 2513.
34. Lewis, N., Rosen, L.S., Rocha Lima, C. et al. Phase I experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. J Clin Oncol 2008, 26(15, Suppl.): Abst 3023.
35. Doss, H.H., Jones, S.F., Infante, J.R. et al. A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors. J Clin Oncol 2008, 26(15, Suppl.): Abst 2567.
36. Ramalingam, S.S., Egorin, M.J., Ramanathan, R.K. et al. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res 2008, 14(11): 3456.
37. Steeghs, N., Gelderblom, H., Roodt, J.O. et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008, 14(11): 3470.
38. Silberman, S., Hwang, J.H., Marshall, J.L. et al. A phase I study of TPI 287, a novel taxane, administered weekly in patients with advanced cancer. J Clin Oncol 2008, 26(15, Suppl.): Abst 2536.
39. Weigang-Kohler, K., Vetter, A., Thyroff-Friesinger, U. Double-blind, randomized clinical phase III study to evaluate the efficacy and safety of HX575, a biosimilar human recombinant epoetin, for the treatment of chemotherapy associated anaemia in cancer patients. Onkologie 2008, 31(Suppl. 1): Abst PE752.
40. New, P.Z., Baskin, D., Trask, T. et al. Radiographic and immunologic responses to adjuvant immunotherapy for malignant gliomas. J Clin Oncol 2008, 26(15, Suppl.): Abst 2039.
41. Nakagawa, H., Kimura, A., Yoshida, M., Motozaki, T., Yoshioka, K., Itoh, K. Evaluation of immunoreactivity of monocarboxylate transporter (MCT) 1 in recurrent and progressive malignant glioma (MG): Speculation of the favorable factor in immunoreactivity in the response to the continuous intrathecal infusion of sodium butyrate (NaB). Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 5532.
42. Sampson, J.H., Archer, G.E., Bigner, D.D. et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J Clin Oncol 2008, 26(15, Suppl.): Abst 2011.
43. Di Tomaso, E., Frosch, M.P., Auluck, P.K. et al. Characterization of blood vessels in brain autopsies of GBM patients who received anti-angiogenic treatment. J Clin Oncol 2008, 26(15, Suppl.): Abst 2009.
44. Van Den Bent, M.J., Wick, W., Liepa, A.M. et al. Time to deterioration in dimensions of health-related quality of life (HRQL) for patients with recurrent glioblastoma multiforme (GBM): Results from the randomized, phase III trial of enzastaurin (ENZ) versus lomustine (CCNU). J Clin Oncol 2008, 26(15, Suppl.): Abst 2040.
45. Fine, H.A., Puduvalli, V.K., Chamberlain, M.C. et al. Enzastaurin (ENZ) versus lomustine (CCNU) in the treatment of recurrent intracranial glioblastoma multiforme (GBM): A phase III study. J Clin Oncol 2008, 26(15, Suppl.): Abst 2005.
46. Shen, S., Lustig, R., Judy, K.D., Fiveash, J.B., Shan, J.S. Open-label, dose confirmation and dosimetry study of interstitial 131I-chTNT-1/B MAb for the treatment of recurrent glioblastoma multiforme (GBM). J Clin Oncol 2008, 26(15, Suppl.): Abst 2072.
47. Rosenfeld, M.R., Chamberlain, M.C., Grossman, S.A. et al. A phase II trial of radiation plus temozolomide followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma multiforme (NABTT #0501). J Clin Oncol 2008, 26(15, Suppl.): Abst 2055.
48. Grossman, S.A., Ye, X., Chamberlain, M.C. et al. Phase II trial of talampanel in conjunction with standard radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM). J Clin Oncol 2008, 26(15, Suppl.): Abst 2014.
49. Verhoeff, J.J., Van Linde, M.E., Lavini, C. et al. Combining metronomic dose temozolomide with bevacizumab in recurrent high grade glioma patients. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 5533.
50. Kirkpatrick, J.P., Rich, J.N., Vredenburgh, J.J. et al. Final report: Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent malignant glioma (MG). J Clin Oncol 2008, 26(15, Suppl.): Abst 2057.
51. De Groot, J.F., Wen, P.Y., Lamborn, K. et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide resistant glioblastoma: NABTC 0601. J Clin Oncol 2008, 26(15, Suppl.): Abst 2020.
52. Conlin, A.K., D'Andrea, G., Hudis, C.A. et al. Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT). J Clin Oncol 2008, 26(15, Suppl.): Abst 1086.
53. Benavides, L.C., Holmes, J.P., Gates, J.D. et al. Results of the first phase I clinical trial of the novel li-key hybrid preventive HER2/ neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03. J Clin Oncol 2008, 26(15, Suppl.): Abst 3016.
54. Dang, C.T., Lin, N.U., Lake, D. et al. Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA). J Clin Oncol 2008, 26(15, Suppl.): Abst 518.
55. Carmichael, M.G., Holmes, J.P., Benavides, L.C. et al. Response to a preventive Her2/neu peptide(E75) vaccine on HER2/neu status. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 2545.
56. Vahdat, L.T., Twelves, C., Allison, M.K. et al. Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy. J Clin Oncol 2008, 26(15, Suppl.): Abst 1084.
57. Philco, M., Falcon, S., Gomez, H., Escandon, R., Saikali, K., Wolff, A. A phase I-II open-label trial of ispinesib on an alternate dosing schedule in chemotherapy-naive patients with locally advanced or metastatic breast cancer (MBC). J Clin Oncol 2008, 26(15, Suppl.): Abst 1143.
58. Gomez, H.L., Doval, D.C., Chavez, M.A. et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008, 26(18): 2999.
59. Campone, M., El-Kouri, C., Cottu, P. et al. French (lapatinib) authorization for temporary use (ATU) - Design, operation and initial safety data. Eur J Cancer Suppl 2008, 6(7): Abst 405.
60. Rodriguez, A., Chang, J., Li, X. et al. Decrease in tumorigenic breast cancer stem cells - Final results of a neoadjuvant trial in primary breast cancer patients. Eur J Cancer Suppl 2008, 6(7): Abst 204.
61. Kaufman, B., Trudeau, M.E., Johnston, S. et al. Clinical activity of lapatinib monotherapy in patients with HER2+ relapsed/refractory inflammatory breast cancer (IBC): Final results of the expanded HER2+ cohort in EGF103009. J Clin Oncol 2008, 26(15, Suppl.): Abst 636.
62. Moy, B., Maltzman, J.D., Rappold, E., Finkelstein, D., Williams, L.S., Goss, P.E. TEACH phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with HER2-overexpressing breast cancer. Eur J Cancer Suppl 2008, 6(7): Abst 244.
63. Beer, M., Lenaz, L., Amadori, D. Phase II study of ortataxel in taxane-resistant breast cancer. J Clin Oncol 2008, 26(15, Suppl.): Abst 1066.
64. Decensi, A., Robertson, C., Guerrieri-Gonzaga, A. et al. A randomized double-blind 2x2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention of high-risk premenopausal women. J Clin Oncol 2008, 26(15, Suppl.): Abst 1503.
65. Mohebtash, M., Madan, R.A., Gulley, J.L. et al. PANVAC vaccine alone or with docetaxel for patients with metastatic breast cancer. J Clin Oncol 2008, 26(15, Suppl.): Abst 3035.
66. Pivot, X., Llombart-Cussac, A., Martin, M., Verrill, M., Peck, R., Conte, P.F. Clinical activity of the novel epothilone B analog, ixabepilone, in triple negative breast cancer (BC) patients. Eur J Cancer Suppl 2008, 6(7): Abst 290.
67. Zhou, X., Segreti, A., Cella, D. et al. Lapatinib plus capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC) - Quality of life (QOL) assessment. Eur J Cancer Suppl 2008, 6(7): Abst 565.
68. Livingston, R.B., Downey, L., Di Leo, A., Koehler, M., Arbushites, M., Williams, L., Press, M.F. Evaluation of chromosome 17 (Chr-17) polysomy in HER2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib. J Clin Oncol 2008, 26(15, Suppl.): Abst 1006.
69. Wu, Y., Segreti, A., Cella, D. et al. Lapatinib plus paclitaxel versus paclitaxel alone for first line metastatic breast cancer (MBC) in ErbB2+ patients - Quality of life (QOL) results. Eur J Cancer Suppl 2008, 6(7): Abst 406.
70. Gray, J.W., Das, D., Wang, N. et al. Identification of a 6 gene molecular predictor of lapatinib related benefit: From breast cancer cell lines to a phase III trial. J Clin Oncol 2008, 26(15, Suppl.): Abst 1043.
71. Press, M.F., Finn, R.S., Di Leo, A. et al. Correlation of HER2 gene amplification, HER2 and EGFR expression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer. J Clin Oncol 2008, 26(15, Suppl.): Abst 1007.
72. O'Shaughnessy, J., Blackwell, K.L., Burstein, H. et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2 + metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008, 26(15, Suppl.): Abst 1015.
73. Schneider, B.P., Karwal, M., Laufman, L. et al. A phase II study of oral MKC-1 metastatic breast cancer (MBC). J Clin Oncol 2008, 26(15, Suppl.): Abst 1046.
74. De Boer, R., Kaufman, P., White, S. et al. Treatment of locally recurrent, unresectable or metastatic breast cancer with AMG 706 plus paclitaxel or docetaxel: Results from a phase 1b study. Eur J Cancer Suppl 2008, 6(7): Abst 582.
75. Aapro, M., Tjulandin, S., Bhar, P., Gradishar, W. Comparison of weekly and every-3-week nab-paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer Suppl 2008, 6(7): Abst 426.
76. Finn, R.S., Gagnon, R., Di Leo, A., Press, M.F., Arbushites, M., Koehler, M. Lapatinib and paclitaxel in HER2-negative, extracellular domain (ECD) positive metastatic breast cancer (MBC) in a randomized phase III study. J Clin Oncol 2008, 26(15, Suppl.): Abst 1017.
77. Northfelt, D.W., Allred, J.B., Liu, H. et al. Phase II trial of paclitaxel polyglumex (PPX) with capecitabine (C) for metastatic breast cancer (MBC). J Clin Oncol 2008, 26(15, Suppl.): Abst 1063.
78. Gelmon, K.A., Fumoleau, P., Verma, S. et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol 2008, 26(15, Suppl,): Abst 1026.
79. Cortés, J., Gelmon, K., Fumoleau, P. et al. Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment. Eur J Cancer Suppl 2008, 6(7): Abst 566.
80. Kaufman, B., Weitzen, R., Goldfarb, A. et al. A single-institution experience from the lapatinib expanded access program - Effect of lapatinib and capecitabine combination therapy on CNS metastases in patients with ErbB2+ metastatic breast cancer. Eur J Cancer Suppl 2008, 6(7): Abst 419.
81. Dieras, V., Viens, P., Veyret, C. et al. Larotaxel (L) in combination with trastuzumab in patients with HER2+ metastatic breast cancer (MBC): Interim analysis of an open phase II label study. J Clin Oncol 2008, 26(15, Suppl.): Abst 1070.
82. Boccardo, F., Kaufman, B., Baselga, J. et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU). J Clin Oncol 2008, 26(15, Suppl.): Abst 1094.
83. Dizon, D.S., Maluf, F., Aghajanian, C.A. et al. Final results of a phase I study of picoplatin and pegylated liposomal doxorubicin in advanced solid tumor malignancies. J Clin Oncol 2008, 26(15, Suppl.): Abst 2568.
84. Witteveen, P., Langenberg, M., Verheul, H.M. et al. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. J Clin Oncol 2008, 26(15, Suppl.): Abst 2530.
85. Mitchell. E.P., LaCouture, M., Shearer, H. et al. Updated results of STEPP, a phase 2, open-label study of the pre-emptive versus reactive skin toxicity treatment in metastatic colorectal cancer (MCRC) patients receiving panitumumab + FOLFIRI or irinotecan-only chemotherapy as second-line treatment. Ann Oncol 2008, 19(Suppl. 6): Abst O-021.
86. Nemunaitis, J.J., Geller, D.A., Karrasch, M. et al. Safety results of a phase I/II study with oncolytic herpes simplex virus, NV1020, administered repeatedly via hepatic artery infusion prior to 2nd-line chemotherapy, in patients with colorectal adenocarcinoma metastatic to the liver. Gastroenterology 2008, 134(4, Suppl. 1): Abst T1928.
87. Kaufman, H.L., Kim-Schulze, S., Kim, D. et al. Correlation of effector and regulatory T cell responses with clinical outcome in metastatic renal cell carcinoma patients treated with MVA-5T4 vaccine and high-dose interleukin-2. J Clin Oncol 2008, 26(15, Suppl.): Abst 3004.
88. Paz-Ares, L., Ross, H., O'Brien, M. et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 2008, 98(10): 1608.
89. Omori, A., Hoffmann, A.C., Shi, M.M. et al. Use of ERCC1 gene expression to predict the effectiveness of platin-based therapy in colorectal, ovarian and lung cancer. J Clin Oncol 2008, 26(15, Suppl.): Abst 2541.
90. Wallis, N., Bulanhagui, C.A., Dorazio, P.C. et al. Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer. J Clin Oncol 2008, 26(15, Suppl.): Abst 3040.
91. Wolchok, J.D. Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment. J Clin Oncol 2008, 26(15, Suppl.): Abst 3020.
92. Hodi, F.S. Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody. J Clin Oncol 2008, 26(15, Suppl.): Abst 3008.
93. Urba, W.J., Weber, J.S., O'Day, S.J., Powderly, J.D., Yellin, M.J., Nichol, G., Hersh, E.M. Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every 3 weeks for 4 doses (induction dosing). J Clin Oncol 2008, 26(15, Suppl.): Abst 3018.
94. Berman, D., Parker, S.M., Chasalow, S.D. et al. Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide. J Clin Oncol 2008, 26(15, Suppl.): Abst 3022.
95. Ghiringhelli, F., Menard, C., Mateus, C., Horn, S., Zitvogel, L., Robert, C. Effect of CTLA-4 blockade on lymphocyte resistance to regulatory T cells in advanced melanoma and use as a surrogate marker of efficacy of tremelimumab. J Clin Oncol 2008, 26(15, Suppl.): Abst 3021.
96. Scott, A.M., Herbertson, R.A., Lee, ET. et al. Phase I biodistribution study of Ley targeting immunoconjugate in advanced epithelial cancers. J Clin Oncol 2008, 26(15, Suppl.): Abst 3025.
97. Digumarti, R., Bapsy, P.P., Shan, J.S. A phase Ib safety and pharmacokinetic study of bavituximab plus chemotherapy in patients with refractory advanced solid tumor malignancies. J Clin Oncol 2008, 26(15, Suppl.): Abst 3038.
98. Leal, T.B., Wilding, G., Eickhoff, J., McNeel, D., Alberti, D., Liu, G. Phase I study of satraplatin and docetaxel in solid malignancies. J Clin Oncol 2008, 26(15, Suppl.): Abst 2570.
99. Yonemori, K., Fujiwara, Y., Minami, H. et al. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci 2008, 99(6): 1237.
100. Lin, N.U., Roché, H.H., Dieras, V. et al. A physician-reported neurological signs and symptoms worksheet (NSS WS) in EGF 105084: A phase II study of lapatinib (lap) for pts with recurrent brain metastases (BM) from HER2+ breast cancer (BC). J Clin Oncol 2008, 26 (15, Suppl.): Abst 1078.
101. Abrey, L.E., Wen, P., Govindan, R. et al. Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label phase II study. J Clin Oncol 2008, 26(15, Suppl.): Abst 2033.
102. Menefee, M.E., Huang, H., Edgerly, M. et al. Effects of the P-glycoprotein (Pgp) antagonist tariquidar (XR-9576; TQD) on Pgp function as well as the toxicity and efficacy of combined chemotherapy in patients with metastatic adrenocortical cancer (mACC). J Clin Oncol 2008, 26(15, Suppl.): Abst 2543.
103. Harrop, R., MacDermott, C., Shablak, A. et al. Vaccination of renal cell cancer patients with TroVax (modified vaccinia Ankara delivering the tumor antigen 5T4) plus 1FN alfa: A phase II trial. J Clin Oncol 2008, 26(15, Suppl.): Abst 3053.
104. O'Brien, S.M., Vey, N., Rizzieri, D.A. et al. A phase I study with CP-4055 in patients with hematologic malgnancies. J Clin Oncol 2008, 26(15, Suppl.): Abst 2532.
105. Shusterman, S., London, W.B., Gillies, S.D. et al. Anti-neuroblastoma activity of hu 14.18-IL2 against minimal residual disease in a Children's Oncology Group (COG) phase II study. J Clin Oncol 2008, 26(15, Suppl.): Abst 3002.
106. Kramer, K., Smith-Jones, P., Humm, J. et al. Therapy of central nervous system (CNS) and leptomeningeal (LM) cancers with intra-Ommaya radioiodine labeled 3F8: Preliminary results of a phase II study. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst LB-74.
107. Löhr, J.M., Arlt, A., Bechstein, W.-O. et al. First line treatment of inoperable pancreatic adenocarcinoma with lipid complexed paclitaxel nanoparticles (EndoTAG-1) plus gemcitabine compared with gemcitabine monotherapy: A prospective randomised controlled phase II study. Gastroenterology 2008, 134(4, Suppl. 1): Abst M2017.
108. Spano, J.P., Chodkiewicz, C., Maurel, J. et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: An open-label randomised phase II study. Lancet 2008, 371(9630): 2101.
109. Kavanagh, J.J., Sill, M.W., Ramirez, P.T., Warshal, D., Pearl, M.L., Morgan, M.A. Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Int J Gynecol Cancer 2008, 18(3): 460.
110. Lhommé, C., Joly, F., Walker, J.L. et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol 2008, 26(16): 2674.
111. Modesitt, S.C., Sill, M., Hoffman, J.S., Bender, D.P. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2008, 109(2): 182.
112. Klisovic, R.B., Blum, W., Wei, X. et al. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res 2008, 14(12): 3889.
113. Karp, J.E., Smith, B.D., Gojo, I. et al. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res 2008, 14(10): 3077.
114. Brentjens, R.J., Hollyman, D., Weiss, M. et al. A phase I trial for the treatment of purine analog-refractory chronic lymphocytic leukemia using autologous T cells genetically targeted to the B cell specific antigen CD19. J Clin Oncol 2008, 26(15, Suppl.): Abst 3045.
115. Quintas-Cardama, A., Kantarjian, H.M., Wieder, E. et al. Randomized phase II study of proteinase 3-derived PR1 vaccine and GM-CSF with or without peg-interferon alfa-2b to eradicate minimal residual disease in chronic myeloid leukemia. J Clin Oncol 2008, 26: Abst 22043.
116. Shah, P., Asastiani, E., Cortes, J. et al. Interim results from a phase I clinical trial of the BCR-ABL inhibitor XL228 in drug-resistant PH- leukemias. Haematologica 2008, 93(Suppl. 1): Abst 0120.
117. Borthakur, G., Alvarado, Y., Ravandi-Kashani, F. et al. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer 2008, 113(2): 360.
118. Ansell, S.M., Horwitz, S., Engert, A. et al. Increased doses of an anti-CD30 antibody, MDX-060, results in prolonged progression free survival in subjects with CD30 positive lymphoma. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 5525.
119. Craig, M., Tallman, M., Boccia, R. et al. Phase II trial of darinaparsin (ZIO-101) in leukemias and lymphomas. Proc Am Assoc Cancer Res (AACR) 2008, 49: Abst 5527.
120. Wilcock, G.K., Black, S.E., Hendrix, S.B., Zavitz, K.H., Swabb, E.A., Laughlin, M.A. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: A randomised phase II trial. Lancet Neurol 2008, 7(6): 483.
121. Dodick, D.W., Galet, V., Ho, T.W. et al. Acute antimigraine efficacy and tolerability of the novel oral CGRP receptor antagonist MK-0974: A phase III clinical trial versus placebo and zolmitriptan. Headache 2008, 48(Suppl.): Abst OR17.
122. Dodick, D.W., Galet, V., Kost, J. et al. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient-level data from a trial of the CGPR receptor antagonist, MK-0974, and zolmitriptan. Headache 2008, 48(Suppl.): Abst S6.
123. Murphy, M.F., Mellberg, S.J., Kurtz, N.M., Graham, E.A. AMPA/kainate receptor antagonist tezampanel is effective in treating acute migraine. Headache 2008, 48(Suppl.): Abst OR18.
124. Comi, G., Pulizzi, A., Rovaris, M. et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 371(9630): 2085.
125. Rascol, O., Poewe, W., Lees, A. et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: The ADVANS Study. Arch Neurol 2008, 65(5): 577.
126. Diener, H.C., Schneider, D., Lampl, Y., Bornstein, N.M., Kozak, A., Rosenberg, G. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke 2008, 39(6): 1774.
127. Joy, S., Rhea, D.J. Who will develop preterm labor during 17alpha-hydroxyprogesterone caproate prophylaxis? Obstet Gynecol 2008, 111(4, Suppl.): Abst.
128. Allen, S.J., O'Brien, J.M., Stanziano, G.J., Barton, J.R. Uterine activity in women receiving 17alpha-hydroxyprogesterone caproate for preterm birth prevention. Obstet Gynecol 2008, 111 (4, Suppl.): Abst.
129. Soyka, M., Koller, G., Schmidt, P. et al. Cannabinoid receptor 1 blocker rimonabant (SR 141716)for treatment of alcohol dependence: Results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 2008, 28(3): 317.
130. McIntyre, R., Panagides, J., Calabrese, J., Hirschfeld, R. Asenapine in bipolar disorder: An overview of clinical trials in the Olympia program. Biol Psychiatry 2008, 63(7, Suppl. 1): Abst 589.
131. Perahia, D.G., Quail, D., Gandhi, P., Walker, D.J., Peveler, R.C. A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression. J Affect Disord 2008, 108(1-2): 33.
132. Feeney, J., Cutler, A.J. The metabolic profile of iloperidone: Summary of phase III schizophrenia trials. Biol Psychiatry 2008, 63 (7, Suppl. 1): Abst 890.
133. Kurtz, D., Mitchell, M., McDonnell, D.P., Bergstrom, R. Pharmacokinetics (PK) of multiple doses of olanzapine long acting injection (OLAI), an intramuscular (IM) depot formulation of olanzapine (OLZ), in stabilized patients with schizophrenia. Biol Psychiatry 2008, 63(7, Suppl. 1): Abst 909.
134. Gopal, S., Lindenmayer, J.-P., Eerdekens, M., Melkote, R., Lim, P., Hough, D. Safety and tolerability of the investigational antipsychotic paliperidone palmitate injected in the deltoid or gluteus muscle in patients with schizophrenia. Biol Psychiatry 2008, 63(7, Suppl. 1): Abst 900.
135. Hough, D., Gopal, S., Eerdekens, M., Lim, P., Morozova, M., Vijapurkar, U. Paliperidone palmitate, an injectable anti-psychotic, in
136. Kramer, M., Litman, R.E., Eerdekens, M., Lim, P., Hough, D., Lane, R. Efficacy and tolerability of paliperidone palmitate: Nine-week, placebo-controlled study in schizophrenia patients. Biol Psychiatry 2008, 63(7, Suppl. 1): Abst 908.
137. Meltzer, H.Y. Pimavanserin, a 5-HT2A inverse agonist, potentiates the efficacy and tolerability of risperidone in the treatment of schizophrenia. Biol Psychiatry 2008, 63(7, Suppl. 1): Abst 429.
138. Mak, S.K., Lo, K.Y., Lo, M.W., Chan, S.F., Tong, G.M., Wong, P.N., Wong, A.K. Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis. Nephrology (Carlton) 2008, 13(4): 331.
139. Safarinejad, M.R. Safety and efficacy of dapoxetine in the treatment of premature ejaculation: A double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology 2008, 33(6): 1259.
140. Mattos, R.M., Marmo Lucon, A., Srougi, M. Tadalafil and fluoxetine in premature ejaculation: Prospective, randomized, double-blind, placebo-controlled study. Urol Int 2008, 80(2): 162.
141. Levine, S.B., Brown, C., Palace, E., Fischkoff, S., Schnorrbusch, C. Phase 2b bremelanotide study in premenopausal and post-menopausal women with female sexual arousal disorder. Obstet Gynecol 2008, 111(4, Suppl.): Abst.
142. Pearlman, S.D., Greos, L., LaForce, C. et al. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol 2008, 101 (1): 90.
143. Marcinkiewicz, J., Wojas-Pelc, A., Walczewska, M. et al. Topical taurine bromamine, a new candidate in the treatment of moderate inflammatory acne vulgaris - A pilot study. Eur J Dermatol 2008, 18 (4) :433.
144. Schwarz, T., Kreiselmaier, I., Bieber, T. et al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol 2008, 59 (1): 34.
145. Buckley, C., Hoffmann, V., Shapiro, J., Saari, S., Cambazard, F., Milsgaard, M. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: A phase II study. Dermatology 2008, 217 (2): 107.
146. Koch, M., Heizmann, W., Nagelschmitz, J., Dalhoff, A. Comparative effects of faropenem-medoxomil and amoxicillin-clavulanate on the normal oral and intestinal micro flora and the selection of penem-resistance. Clin Microbiol Infect 2008, 14(Abstracts Issue): Abst P574.
147. Vestergaard, E.T., Djurhuus, C.B., Gjedsted, J. et al. Acute effects of ghrelin administration on glucose and lipid metabolism. J Clin Endocrinol Metab 2008, 93(2): 438.
148. Saaka, M., Okoko, B.J., Kohberger, R.C. et al. Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia. Vaccine 2008, 26(29-30): 3719.
149. Okoko, J., Saaka, M., Kohberger, R.C. et al. The serotype-specific efficacy and immunogenicity of a 9-valent pneumococcal conjugate vaccine determined during an efficacy trial in the Gambia, West Africa. Clin Microbiol Infect 2008, 14(Abstracts Issue): Abst P1334.
150. Boyce, M.J., Carey, W., Mannaert, E.J., Mertens, A., Ausma, J. Cardiovascular safety of prucalopride (RESOLOR) in healthy subjects: Results from a randomized, double-blind, placebo-controlled, cross-over trial. Gastroenterology 2008, 134(4, Suppl. 1): Abst T1418.
151. Jordan, R., Jones, K., Bolken, T. et al. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antivir Res 2008, 78(2): Abst 41.
152. Van der Schueren, B.J., Blanchard, R., Murphy, M.G. et al. Effect of MK-0974, an oral CGRP antagonist, on the hemodynamic response to subligual nitroglycerin. Headache 2008, 48(Suppl.): Abst S58.
153. Yuan, Y., Chen, Y., Hunt, R.H. Dose-effect of S-tenatoprazole-Na in healthy volunteers: A meta-analysis of individual subject data from four pharmacodynamic studies. Gastroenterology 2008, 134(4, Suppl. 1): Abst S1093.
154. Khanna, N., Dalby, R., Connor, A., Church, A., Stern, J., Frazer, N. Phase I clinical trial of repeat dose terameprocol vaginal ointment in healthy female volunteers. Sex Transm Dis 2008, 35(6): 577.
155. Wloch, M.K., Smith, L.R., Boutsaboualoy, S. et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008, 197(12): 1634.